{
  "id": 20444266,
  "title": "FDA Clears Novartis Drug Cosentyx As Steroid Alternative for Inflammatory Pain Causing Stiff Shoulders",
  "url": "https://urgent.news/2026/11/17/fda-clears-novartis-drug-cosentyx-as-steroid-alternative-for",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-17T14:24:14.000Z",
  "source": {
    "name": "Benzinga",
    "slug": "benzinga",
    "url": "https://www.benzinga.com/news/fda/26/11/63340274/fda-clears-novartis-drug-cosentyx-as-steroid-alternative-for-inflammatory-pain-causing-stiff-shoulders"
  },
  "original_language": "en",
  "account": "The U.S. Food and Drug Administration (FDA) recently granted approval to Novartis AG's (NYSE:NVS) Cosentyx (secukinumab) 150 mg for treating adults with polymyalgia rheumatica (PMR) who are not adequately responding to corticosteroids or cannot tolerate a corticosteroid taper. This marks Cosentyx as the first and only anti-interleukin-17 (anti-IL-17) biologic specifically approved for PMR, providing rheumatologists with an alternative to long-term steroid therapy supported by over a decade of clinical experience in managing immune-mediated diseases. PMR affects approximately 966,000 people in the U.S., primarily adults aged 50 and older. It causes acute pain and stiffness in the shoulders, neck, and hips, significantly diminishing daily quality of life. Physicians often rely on long-term steroids as the standard treatment, but up to 40% of patients experience relapses within the first year, and prolonged steroid use increases the risk of severe complications such as osteoporosis, cardiovascular disease, and diabetes. The FDA's decision was based on the global Phase 3 REPLENISH trial, which showed that Cosentyx 150 mg doubled remission rates compared to a placebo when combined with a 24-week steroid taper. At week 52 following the steroid taper, adults taking Cosentyx 150 mg achieved sustained remission at a rate of 40.5%, compared to 20.5% among placebo recipients. The study also measured complete sustained remission at week 52, adjusted annual cumulative steroid doses, and the time until patients required escape or rescue therapy.",
  "summary": "On Tuesday, the U.S. Food and Drug Administration (FDA) approved Novartis AG’s (NYSE:NVS) Cosentyx (secukinumab) 150 mg to treat adults with polymyalgia rheumatica (PMR) who respond inadequately to corticosteroids or cannot tolerate a corticosteroid taper. The regulatory decision establishes Cosentyx as the first and only anti-interleukin-17 (anti-IL-17) biologic for PMR, giving rheumatologists…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}